All of us here at Thalocan Research Innovations applaud the work of The American Academy of Dermatology in designating November as National Healthy Skin Month. It is indeed an awareness month for all. At TRI we are proud to continue our goal to revolutionize the assessment of dermatological diseases with the latest technology, designed to enhance every…
DetailsAt SHSA 2025 in Nashville this past weekend, one of the primary topics discussed at our booth was the urgent needed for standardizing assessment for Hidradenitis Suppurativa. Being aware of the various ways that raters are CURRENTLY mapping lesions and how that process can be improved and standardized provided us with the roadmap we needed…
DetailsEric Zudak, CEO of Thalocan Research Innovations, discusses Thalocan’s role in helping to address unmet needs in the immunodermatology area. With many, if not most inflammatory skin diseases being more common in Skin of Color than in lighter pigmented skin – Thalocan is proud to provide cutting edge technology, training and tools for more accurate scientific…
DetailsWe are very excited to share our UPDATED comprehensive VASI training course! Authored by Dr. Iltefat Hamzavi, this enhanced training was designed by Thalocan Research Innovations to improve efficiency in clinical trial training management and support consistent severity assessment in #vitiligostudies. Please contact licensing@thalocan.com for details.
Looking forward to (nearly all of) our Thalocan Research Innovations Team meeting friends old and new at SHSA 2025 in Nashville, where we are a proud Bronze Sponsor! We have put a great deal of time and energy towards solutions to improve data quality, as well as patient experience and Investigator satisfaction. SHSA 2025 will…
DetailsDr. Amit Garg shares his experience with the unique challenges of disease assessment and measuring treatment response in Hidradenitis Suppurativa. At Thalocan Research Innovations we collaborate with experts like Dr. Garg and Dr. John Ingram, among others, to develop tools and applications that improve the experience for trialists and patients, as well as optimizing the…
DetailsWe are grateful to Dr. Steve Daveluy for his comments regarding trainings provided by Thalocan Research Innovations, including our Hidradenitis Suppurativa Clinical Trial training led by Dr. Amit Garg and Dr. John Ingram. You can view a portion of that here or learn about our other training curriculums by visiting www.thalocan.com/trainings
More than 204 million people worldwide (or 2.6% of the world’s population) experience eczema. During October, we here at Thalocan Research Innovations are honored to join health organizations and dermatology groups work to continue to educate the public on eczema and reduce the stigma surrounding this chronic inflammatory skin condition. Of special note is the…
DetailsMeet (most) of the Thalocan Research Innovations team at SHSA 2025 in Nashville, the 10th annual symposium on Hidradenitis Supprativa. Here at TRI we are working alongside a number of KOLs including Dr. Amit Garg and Professor John Ingram, in creating technology and training to improve clinical trials and aid in the assessment and…
DetailsThalocan Research Innovations celebrates the fine work of the National Alopecia Areata Foundation and we are proud to spread awareness of their third annual Walk for Alopecia. (link to our blog) With Flagship Sites in San Francisco and Philadelphia, 20+ Volunteer Led Community Sites around the country, and locally activating do-it-yourself Walk Where You Are…
Details
